Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).
Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.
Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.
Top-decile sponsor footprint
Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,845 total, page 12 of 37
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
NCT03502616
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
NCT03573882
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
NCT03550313
PF-06741086 Long-term Treatment in Severe Hemophilia
NCT03363321
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX
NCT03975790
Glasdegib Renal Impairment Study
NCT03596567
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
NCT03530683
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
NCT03000439
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
NCT03472560
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
NCT03492697
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
NCT03539601
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
NCT03416179
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
NCT03448172
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
NCT03529773
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT03439514
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
NCT03329092
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822
A Study of PF-06873600 in People With Cancer
NCT03519178
Treatment AND Monitoring Patterns AND Clinical Outcomes IN Patients Receiving Palbociclib Combination Treatment (with AI OR Fulvestrant) FOR Hr+/her2- A/mbc IN A Community Oncology Setting.
NCT04498481
Trial in Adult Subjects With Acute Migraines
NCT03461757
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
NCT03395184
A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects
NCT03398473
A Study In Adults With Moderate To Severe Dermatomyositis
NCT03181893
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
NCT03362502
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
NCT03356977
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
NCT03864042
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT03317496
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
NCT03269695
Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
NCT03309202
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
NCT03349060
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT03269136
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
NCT03281304
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
NCT03351751
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
NCT03031938
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
NCT03284723
A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers
NCT03273842
A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
NCT02863575
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03330405
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
NCT03271047
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
NCT03309241
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
NCT03313050
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
NCT03313037
6-week Safety and PD Study in Adults With NAFLD
NCT03256526
PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations
NCT03112148
Glasdegib Absolute Bioavailability Study
NCT03270878
Understanding Hemophilia A and B Drug Dosage Administration Patterns
NCT03248141
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 703 |
| Phase 2 | 470 |
| Phase 3 | 411 |
| Phase 4 | 93 |
Therapeutic Areas
What is open in the Pfizer pipeline
106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).
Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).
Top condition: Healthy (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pfizer: open-pipeline peers nationwide
Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,845 trials (± recruiting share)
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Duke University · 1,725 trials · 11% recruiting
- University of California, San Francisco · 1,713 trials · 16% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pacira Pharmaceuticals · 6% recruiting · 88 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this Pfizer page
1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.
- 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.